The vaccine candidate would be the first to be made based on a widely used vaccine without the assistance and approval of the developer.
It is also the first mRNA vaccine designed, developed and produced at lab scale on the African continent.
The World Health Organization (WHO) last year picked a consortium, including Afrigen, for a pilot project to give poor and middle-income countries the know-how to make Covid-19 vaccines, after market leaders of the mRNA Covid vaccine, Pfizer, BioNTech and Moderna declined a WHO request to share their technology and expertise.
The WHO and partners hope the hub will help overcome glaring inequalities between rich nations and poorer countries in accessing vaccine doses, with 99% of all of Africa's vaccines imported and the negligible remainder manufactured locally.
During the pandemic, wealthy countries have hoovered up most of the world's supplies of vaccines.
Biovac, a partly state-owned South African vaccine producer, will be the first recipient of the technology from the hub.
Afrigen has also agreed to help train companies in Argentina and Brazil.
In September, the WHO hub in Cape Town decided to go it alone after failing to bring on board Pfizer and Moderna, both of which have argued they need to oversee any technology transfer due to the complexity of the manufacturing process.
Moderna's vaccine was chosen due to an abundance of public information and its pledge not to enforce patents during the pandemic.
It's not clear what will happen after that.
The UN-backed Medicines Patent Pool (MPP) said it was in talks with Moderna about possible access to some of its patents
Under pressure to make drugs in lower-income countries, Moderna and BioNTech have announced plans to build mRNA vaccine factories in Africa, but production is still a long way off.
Biovac has agreed to fill and finish the Pfizer-BioNTech vaccine, the final stages of production, although the drug substance will come from Europe.
Speaking to media and delegates at the launch, Petro Terblanche, managing director at Afrigen, said the company did not copy Moderna, they instead developed their own processes because Moderna didn't give any technology.
She also said it had managed to make, in collaboration with Johannesburg's University of the Witwatersrand (Wits University), its first micro-litre laboratory scale batches of Covid-19 mRNA vaccines at the Cape Town facility.
Terblanche added that they are working on a next generation mRNA vaccine that didn't need freezing temperatures for storage, required for the Pfizer and Moderna doses, and which would be better suited to the hot conditions of Africa with its poorer health facilities and infrastructure.
Reuters, the news and media division of Thomson Reuters, is the world's largest multimedia news provider, reaching billions of people worldwide every day.
Go to: https://www.reuters.com/
